Lucid Diagnostics Inc (NASDAQ:LUCD) currently has a daily average trading volume of 507.84K but it saw 852472 shares traded in last market. With a market cap of 94.35M USD, the company’s current market price of $1.59 remained unchanged while comparing to the previous closing price of $1.59. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.60 and as low as $0.63.
Taking a look at 20-day trading activity of Lucid Diagnostics Inc (LUCD) gives us an average price of $1.0938, while its current price level is -0.62% below from 52-week high level whereas it is 152.34% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.9245 while that of 200 days or SMA-200 reads an average of $0.8758. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.38% during that period while stretching the period over a month that decreases to 8.54%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 89.05 which implies that the stock is in overbought territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Ascendiant Capital Markets which initiated the stock as “Buy” in its note to investors issued on December 27, 2021, recommending a price target of $16 for it. Cantor Fitzgerald also issued its recommendations for the stock as it initiated the price target for the stock is $21.
Over the week, LUCD’s stock price is moving 24.22% up while it is 88.66% when we observe its performance for the past one month. Year-to-date it is 94.21% up and over the past year, the stock is showing an upside performance of 16.06%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -0.15 while estimate for next year EPS is -0.76. In next quarter, company is expected to be making quarterly sales of $1.61M as analysts are expecting the sales for current fiscal year at $4.57M and seeing the company making $10.92M in sales next year. Moreover, analysts are in estimates of $1.42M for current-quarter revenue.
Currently, Lucid Diagnostics Inc’s total number of outstanding shares is 51.60M with 60.83% of that held by the insiders while 5.61% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -626.59% and return on equity (ROE) at -1007.83%. Stock’s beta reads 1.54. Stock has a price to sale or P/S ratio amounts to 22.52. Its return on asset (ROA) is -160.52% on average.
